Aquinox Pharmaceuticals (AQXP): Dumped By Big Pharmas

Johnson & Johnson and Pfizer both pruned their holdings in Aquinox Pharmaceuticals following the recent run-up in its shares. Aquinox Pharmaceuticals (AQXP) soared recently after the company announced positive results from secondary endpoints from its Phase 2 LEADERSHIP trial with AQX-1125 in patients with bladder pain syndrome/interstitial cystitis (BPS/IC). Aquinox’s improved quarterly earnings As outlined by ValueWalk, Aquinox Pharmaceuticals unveiled its second quarter results wherein the clinical stage pharmaceutical company reported that its net loss declined to $4.8 million from $5.4 million in the same period a year ago. The firm ended the quarter with $29 million in cash, cash…